LP-118

Phase 2Small molecule

NNewave Pharmaceutical Inc

LP-118 is one of 81 small molecule programs targeting Relapsed or Refractory. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed or RefractoryRecruiting

Acute Lymphoblastic LeukemiaRecruiting

Relapsed or RefractoryPhase 1

Recruiting

Acute Lymphoblastic LeukemiaPhase 2

Recruiting

Competition

Competitive Landscape

163 competitors in Acute Lymphoblastic Leukemia

#DrugCompanyPhaseTrials

Adriamycin

Pfizer

Phase 3

40 2

Oncovin

Eli Lilly

Phase 3

75 3

Oncaspar

SServier

Phase 3

48 4

Elspar

DDutch Childhood Oncology Group

Phase 3

45 5

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

43 6

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

40 7

Fludara

Sanofi

Phase 3

15 8

Medrol

Pfizer

Phase 3

12 9

Iclusig

Cellcept

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Acute Lymphoblastic Leukemia

NCT06207123

Clinical

Trials by Indication[1]

Advanced1 trial

A Study of LP-118 in Patients With Advanced Tumors

Completed·GGuangzhou Lupeng Pharmaceutical Company LTD.·Phase 1·NCT05025358·68 enrolled

Acute Lymphoblastic Leukemia1 trial

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Recruiting·UUniversity of Chicago·Phase 1/2·NCT06207123·15 enrolled

Relapsed or Refractory1 trial

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Recruiting·NNewave Pharmaceutical Inc·Phase 1·NCT04771572·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for LP-118. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LP-118 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LP-118. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Newave Pharmaceutical Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNewave Pharmaceutical Inc

LP-118

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Advanced1 trial

Acute Lymphoblastic Leukemia1 trial

Relapsed or Refractory1 trial

References

Drug Info

Quick Facts

Related News